Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELENE 3: AZD6234 add-on to incretin therapy in adults with obesity or overweight with weight-related comorbidities, with or without type 2 diabetes
CTR20263929Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Aug 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of lenbelintide in obesity, Overweight, type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Aug 2026; status: active.
02
Drugs
lenbelintide
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20263929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263929.